| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.93B | 2.03B | 2.08B | 3.54B | 3.67B | 3.55B |
| Gross Profit | 1.04B | 1.06B | 1.03B | 1.08B | 1.12B | 1.15B |
| EBITDA | 323.38M | 182.38M | 177.28M | 294.23M | 251.96M | 83.01M |
| Net Income | 74.98M | 10.24M | -385.63M | 36.94M | 3.51M | -190.49M |
Balance Sheet | ||||||
| Total Assets | 3.26B | 3.40B | 4.27B | 4.74B | 4.96B | 5.22B |
| Cash, Cash Equivalents and Short-Term Investments | 335.97M | 486.10M | 622.22M | 681.15M | 746.92M | 940.42M |
| Total Debt | 2.23B | 2.05B | 2.30B | 2.57B | 2.56B | 2.81B |
| Total Liabilities | 3.92B | 3.98B | 4.64B | 4.68B | 4.85B | 5.15B |
| Stockholders Equity | -661.54M | -578.43M | -368.58M | 60.65M | 112.63M | 70.62M |
Cash Flow | ||||||
| Free Cash Flow | 227.83M | 156.77M | -23.41M | 51.14M | 117.47M | 196.99M |
| Operating Cash Flow | 296.04M | 229.17M | 79.47M | 175.98M | 301.51M | 301.97M |
| Investing Cash Flow | -93.24M | -49.06M | -122.83M | -24.27M | -155.25M | -75.69M |
| Financing Cash Flow | -439.82M | -305.45M | -31.27M | -198.08M | -330.37M | -235.37M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | $21.03B | 25.74 | 36.47% | 1.02% | 12.54% | 19.59% | |
79 Outperform | $72.26B | 17.05 | 15.87% | 1.94% | 3.09% | 14.94% | |
72 Outperform | $89.43B | 16.53 | 33.67% | 6.55% | -1.25% | -2.25% | |
67 Neutral | $19.41B | 35.55 | 15.13% | 0.89% | -1.60% | 4.87% | |
67 Neutral | $5.11B | 38.93 | 14.41% | 2.56% | -0.74% | -32.79% | |
63 Neutral | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% | |
51 Neutral | $1.64B | 24.35 | ― | 2.82% | -35.52% | ― |
On December 22, 2025, Pitney Bowes announced that its cash tender offers for its 6.70% Notes due 2043 and 5.250% Medium-Term Notes due 2037 had expired, following an increase in the maximum aggregate principal amount to be purchased from $75 million to $80 million. The offers, which expired on December 19, 2025, resulted in approximately $79.9 million in aggregate principal amount of notes being validly tendered and not withdrawn, allowing the company to accept all tendered notes without proration, effectively retiring a portion of its long-dated debt and refining its capital structure.
The most recent analyst rating on (PBI) stock is a Hold with a $11.00 price target. To see the full list of analyst forecasts on Pitney Bowes stock, see the PBI Stock Forecast page.
On November 21, 2025, Pitney Bowes announced the commencement of cash tender offers to purchase up to $75 million of its outstanding 6.70% Notes due 2043 and 5.250% Medium-Term Notes due 2037. The tender offers, which are set to expire on December 19, 2025, allow the company to manage its debt obligations strategically, potentially impacting its financial operations and market position. The company intends to finance these purchases with cash on hand, and the offers are subject to certain conditions and acceptance priority levels.
The most recent analyst rating on (PBI) stock is a Hold with a $9.43 price target. To see the full list of analyst forecasts on Pitney Bowes stock, see the PBI Stock Forecast page.